IBS and mental health: Anatara Lifesciences to trial supplement that targets colon and small intestine delivery

15 MARCH 2021 NUTRAingredients

Tingmin Koe

Anatara CEO, Steven Lydeamore, was recently interviewed by NUTRAingredients Editor, Tingmin Koe, about how a subset of Anatara’s Gastrointestinal ReProgramming (GaRP) complementary medicine, “3FDC” which specifically targets the colon is to trialled in an upcoming human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms.

Click the following link for access to the article – https://www.nutraingredients-asia.com/Article/2021/03/15/IBS-and-mental-health-Anatara-Lifesciences-to-trial-supplement-that-targets-colon-and-small-intestine-delivery?fbclid=IwAR2wC6T0FmNIgZwJuuR_muv29bB_77n9xKhZzFMxoUk5fOgRJS4B2gZ6o5Q

NutraIngredients has been the leading online news source for the nutrition industry for more than 15 years, providing a 360-degree view of the global functional food and supplement market, spanning everything from investment, incubation and innovation, to ingredients, food science and product formulation, labelling, litigation, regulation, consumer trends, new products and new technology.